Tuition Reference

COLUMBIA, Md., July 29, 2010 (BUSINESS WIRE) — Osiris Therapeutics, Inc. /quotes/comstock/15*!osir/quotes/nls/osir (OSIR 7.95, +0.25, +3.25%) currently voiced which it will inform a monetary formula for a entertain finished Jun 30, 2010, upon Friday, Aug 6, 2010. C. Randal Mills, Ph.D., President as good as Chief Executive Officer, as good as Philip R. Jacoby, Jr., Chief Financial Officer, will yield a association refurbish as good as plead formula around a webcast as good as discussion call upon Friday, Aug 6, 2010 during 9:00 a.m. ET.

To entrance a webcast, revisit a Investor Relations territory of a company’s website during http://investor.osiris.com/events.cfm. Alternatively, callers might experience in a discussion call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants).

A replay of a discussion call will be accessible we estimate dual hours after a execution of a call by Aug 19, 2010. Callers can entrance a replay by dialing (800) 642-1687 (U.S. participants) or (706) 645-9291 (international participants). The audio replay acknowledgment formula is 89024964. To entrance a replay of a webcast, revisit a Investor Relations territory of a company’s website during http://investor.osiris.com/events.cfm.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a heading branch dungeon healing association focused upon building products to provide critical healing conditions in a inflammatory, autoimmune, orthopedic as good as cardiovascular areas. The Company’s tube of internally grown biologic drug possibilities underneath analysis includes Prochymal for inflammatory, autoimmune as good as cardiovascular indications, as good as Chondrogen for arthritis in a knee. Osiris is a entirely integrated company, with capabilities in research, development, production as good as placement of branch dungeon products. Osiris has grown an endless egghead skill portfolio to strengthen a company’s technology, together with 49 U.S. patents any carrying a single or some-more unfamiliar counterparts. Osiris, Prochymal as good as Chondrogen have been purebred trademarks of Osiris Therapeutics, Inc. More report can be found upon a company’s website, www.Osiris.com. (OSIR-G)

Osiris as good as Genzyme shaped a vital fondness for a growth as good as commercialization of Prochymal as good as Chondrogen. Under a conditions of a agreement, Osiris retains commercialization rights to Prochymal as good as Chondrogen in a United States as good as Canada. Genzyme binds these rights in all alternative countries solely Japan, where JCR Pharmaceuticals binds rights to Prochymal for a diagnosis of patients with hematological malignancies.

Forward-Looking Statements

This press recover contains forward-looking statements. Forward-looking statements embody statements about a expectations, beliefs, plans, objectives, intentions, assumptions as good as alternative statements which have been not chronological facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or identical difference or phrases, or a negatives of those difference or phrases, might brand forward-looking statements, though a deficiency of these difference does not indispensably meant which a matter is not forward-looking. Examples of forward-looking statements include, though have been not singular to, statements per a following: a product growth efforts; a clinical trials as good as approaching regulatory mandate as good as a capability to successfully navigate these requirements; a success of a product possibilities in development; standing of a regulatory routine for a biologic drug candidates; doing of a corporate strategy; a monetary performance; a product investigate as good as growth activities as good as projected expenditures, together with a approaching timeline as good as clinical plan for Prochymal, Chondrogen as good as a alternative MSC as good as biologic drug candidates; a money needs; patents as good as exclusive rights; a reserve as good as capability of a intensity products to provide mildew as good as a formula of a systematic research; a skeleton for sales as good as marketing; a skeleton per a facilities; sorts of regulatory frameworks we pattern will be germane to a intensity products; as good as formula of a systematic research. Forward-looking statements have been theme to well known as good as different risks as good as uncertainties as good as have been formed upon potentially false assumptions which could means tangible formula to talk about materially from those approaching or pragmatic by a forward-looking statements. Risks as good as uncertainties associated to a Collaboration Agreement with Genzyme for a growth as good as commercialization of Prochymal as good as Chondrogen include, between others: standard commercial operation transactional risks; risks associated to product growth as good as clinical hearing design, opening as good as completion; doubt of a success of Prochymal as good as Chondrogen in clinical trials as good as their capability to provide disease; Genzyme’s early stop as good as opt-out rights; a capability of Osiris as good as Genzyme to successfully navigate regulatory mandate as good as to make as good as commercialize products; as good as a doubt as to a capability to successfully perform underneath a collaborative agreement as good as consequence miracle as good as kingship payments thereunder. Our tangible formula could talk about materially from those approaching in forward-looking statements for most reasons, together with a factors described in a territory entitled “Risk Factors” in a Annual Report upon Form 10-K as good as alternative Periodic Reports filed upon Form 10-Q, with a United States Securities as good as Exchange Commission. Accordingly, we should not unduly rest upon these forward-looking statements. We commence no requisite to publicly correct any forward-looking matter to simulate resources or events after a date of this press recover or to simulate a feeling of amazing events.

SOURCE: Osiris Therapeutics, Inc.

 Osiris Therapeutics, Inc. Erica Elchin, 443-545-1834 OsirisPR[at]Osiris.com or Media: Schwartz Communications Andrew Law/Rachel Gross, 781-684-0770 Osiris[at]schwartz-pr.com 

Copyright Business Wire 2010